First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
First and only PARP inhibitor to improve invasive disease-free survival in patients
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
63-year old woman gets rare Transcatheter Tricuspid Valve Replacement (TTVR)
Apollo Hospitals Chennai is the first healthcare institution in South India to use this protected TAVI / TAVR technology.
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Based on a post hoc analysis, fewer required respiratory interventions
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Subscribe To Our Newsletter & Stay Updated
